BEACON: A randomised, phase 3 study of encorafenib and cetuximab plus /- binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer patients
Authors
Wasan, HArkenau, T
Braun, Michael S
Samuel, L
Graham, J
Kopetz, S
Grothey, A
Van Cutsem, E
Yaeger, R
Yoshino, T
Desai, J
Ciardello, F
Gollerkeri, A
Maharry, K
Sandor, V
Christy-Bittel, J
Anderson, L
Tabernero, J
Affiliation
Hammersmith Hospital, London,Issue Date
2019